Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 8,274 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Risk Clear all

Conditions: Obesity
Interventions: 2N Trout, 3N Trout, Tilapia; Other
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 20 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Embolism, Pneumonia, Congestive Heart Failure
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depression, Substance-Related Disorders, HIV Infections
Interventions: Antidepressant Medication; Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Anal Squamous Cell Carcinoma
Interventions: Radiotherapy - Low risk group, Radiotherapy - Standard risk group, Radiotherapy - Intermediate risk group, Radiotherapy - High risk group; Radiation
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Milwaukee, Wisconsin

Conditions: Muscle Weakness, Critical Illness
Interventions: Not listed
Lead sponsor: Naeem Ali, MD; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Indianapolis, Indiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Eating Disorder
Interventions: The Body Project: More Than Muscles; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: PTSD, Cardiovascular Disease, Cardiovascular Disease Risk Factors
Interventions: Exercise; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer
Interventions: Erlotinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Acute Coronary Syndrome
Interventions: veliflapon (DG-031); Drug
Lead sponsor: deCODE genetics; Industry
Eligibility: 35 Years and older
Enrollment: 3,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 11
States / cities: Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more

Conditions: Candidiasis
Interventions: Fluconazole, AmBisome; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hepatitis C, Atherosclerosis
Interventions: Patient counseling for HCV associated CVD risk factors; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Glaucoma, Diabetic Retinopathy, Refractive Errors, Cataract, Behavior, Health
Interventions: No Financial Incentive, Financial Incentive; Other · Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Leukemia
Interventions: Dose Level 1, Dose Level 2, Dose Level 3; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Sepsis, Acute Kidney Injury, Septic Shock
Interventions: Subject management guided by NephroCheck® test, Standard of Care; Device · Other
Lead sponsor: BioMérieux; Industry
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Shreveport, Louisiana • Boston, Massachusetts • New York, New York

Conditions: Biomarkers
Interventions: Sugar sweetened beverage (SSB); Other
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 30 Years to 55 Years · Female only
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hernia, Ventral, Weight Loss
Interventions: Prehabilitation, Standard counseling; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 128
States / cities: Daphne, Alabama • Mobile, Alabama • Goodyear, Arizona + 94 more

Conditions: Prostate Cancer
Interventions: Two-Fraction Stereotactic Body Radiation Therapy (SBRT); Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 2
States / cities: Mineola, New York • New York, New York

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Interventions: ASP7517; Biological
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Duarte, California • Pembroke Pines, Florida • New York, New York

Conditions: Myelodysplastic Syndromes
Interventions: decitabine, azacitidine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Stanford, California • Stockton, California + 16 more

Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
Interventions: Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 925 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 63
States / cities: Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more

Conditions: Severe Aortic Stenosis, Cardiogenic Shock, Cardiogenic Shock, ECMO, Trans-catheter Aortic Valve Implantation
Interventions: Left Atrial Veno-Arterial Extracorporeal Membrane Oxygenation (LAVA-ECMO); Device
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Detroit, Michigan • Morristown, New Jersey

Search by objective public record fields.

Disease Risk Reduction and Omega-3 Rich Rainbow Trout (Fish for Health)

Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing

Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder

Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

New Onset Weakness in Critically Ill Patients and the Risk of Death and Recurrent ICU Admission

Genetic Factors in Atherosclerosis

Reducing Eating Disorder Risk Factors Among College-Aged Males

Determining the Benefits of Exercise on Cardiovascular Risk in PTSD

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

Counseling Hepatitis C Virus (HCV) Positive Patients for Cardiovascular Disease Risk Factors

Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)

Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women

Modifying Risk in Ventral Hernia Patients

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Two Fraction Prostate SBRT With DIL SIB

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR